Overview

GUSKA is an AI-powered biotech developing programmable RNA-based oncolytic virotherapies for aggressive solid tumors. By combining synthetic virology, proprietary viral attenuation technologies, and generative AI, GUSKA designs therapeutic candidates intended to selectively destroy cancer cells, release neoantigens and inflammatory signals, and activate anti-tumor immunity. GUSKA is advancing a pipeline focused on hard-to-treat cancers such as glioblastoma and pancreatic cancer.